Grant: Project Grant
University of Toronto
$100,000.00
Investigating the novel stem cell function of the phosphoinositide phosphatase INPP4B in hematopoiesis and leukemia
EF 2016-17
Résumé
Current views suggest that within a single tumor, not all cancer cells are created equal. This notion indicates that to cure cancer we must be able to eradicate all different cell types, or run the risk of a relapsed disease. A fitting analogy is to think of cancer as a weed, with leaves at the top that are sustained by roots at the bottom. Cancer, just like a 'weed', can only be killed if the roots are removed entirely. A particularly challenging example of such a cancer (weed) is acute myeloid leukemia (AML), where the (roots) leukemic stem cells (LSC) are the drivers of primary disease and relapse after a successful initial therapy.
In our goal to eliminate the root we first, have to understand LSC biology. Our efforts have identified several genes that appear to be essential for LSC function and survival. The goal of this project is to validate the emerging role and clinical importance of one of the most promising of these candidate genes, namely INPP4B, in LSC function and AML progression. Our group recently identified INPP4B as a biomarker for AML patients with poor outcome. In our attempts to understand how this gene contributes to poor disease in patients we have generated promising data that INPP4B plays a critical role in LSC biology suggesting that it could be a novel target to improve AML treatment.
To fulfill the aims of this grant I have assembled a collaborative team of world leading AML and stem cell scientists with unparalleled collective resources including AML patient samples, transplant models, knockout mice, next generation sequencing and proteomic profiling platforms. Together we aim to draw a comprehensive picture of INPP4B function in normal and leukemia stem cells and work towards understanding its utility in AML therapy. In the next five years we aim to identify how INPP4B promotes AML and develop strategies to use this knowledge to generate new AML therapies.
Programme
Project Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
351773
Name
Salmena Leonardo L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Investigating the novel stem cell function of the phosphoinositide phosphatase INPP4B in hematopoiesis and leukemia
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Acute Myeloid Leukemia; Aml Prognosis; Chemotherapy Resistance; Hematopoiesis; Inpp4b; Leukemia; Phosphoinositide Signalling; Stem Cell
Abstract
Current views suggest that within a single tumor, not all cancer cells are created equal. This notion indicates that to cure cancer we must be able to eradicate all different cell types, or run the risk of a relapsed disease. A fitting analogy is to think of cancer as a weed, with leaves at the top that are sustained by roots at the bottom. Cancer, just like a 'weed', can only be killed if the roots are removed entirely. A particularly challenging example of such a cancer (weed) is acute myeloid leukemia (AML), where the (roots) leukemic stem cells (LSC) are the drivers of primary disease and relapse after a successful initial therapy.
In our goal to eliminate the root we first, have to understand LSC biology. Our efforts have identified several genes that appear to be essential for LSC function and survival. The goal of this project is to validate the emerging role and clinical importance of one of the most promising of these candidate genes, namely INPP4B, in LSC function and AML progression. Our group recently identified INPP4B as a biomarker for AML patients with poor outcome. In our attempts to understand how this gene contributes to poor disease in patients we have generated promising data that INPP4B plays a critical role in LSC biology suggesting that it could be a novel target to improve AML treatment.
To fulfill the aims of this grant I have assembled a collaborative team of world leading AML and stem cell scientists with unparalleled collective resources including AML patient samples, transplant models, knockout mice, next generation sequencing and proteomic profiling platforms. Together we aim to draw a comprehensive picture of INPP4B function in normal and leukemia stem cells and work towards understanding its utility in AML therapy. In the next five years we aim to identify how INPP4B promotes AML and develop strategies to use this knowledge to generate new AML therapies.
Competitiondate
201604
Approvedterm2
1 yr 0 mth
Pinamesdelim
Salmena, Leonardo L
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~